A three-year study of GA Depot, a monthly injection for primary progressive multiple sclerosis (PPMS), found that most patients experienced no disability progression, with some even showing slight improvements in mobility. These interim results from a Phase 2a clinical trial will be presented tomorrow by developer Mapi Pharma…
GA Depot
Recommended Posts
- New method confirms positive clinical trial results for MS drug Tecfidera
- AAN 2026: AI-powered MS blood test sees growing use in real-world care
- AAN 2026: Ocrevus preserves walking, hand function in early RRMS
- My husband’s MS diagnosis changed everything — and nothing
- Enrollment complete in Phase 3 trial of at-home Briumvi injection for MS